An Open-Label, Single-Arm, 3-Year Extension Study to Evaluate Safety and Tolerability of Tinlarebant in Subjects with Stargardt Disease

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-522460-33-00

Enrollment

Registered

2026-04-07

Start date

Unknown

Completion date

Unknown

Last updated

2026-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stargardt Disease

Brief summary

Change in DDAF (Definitely decreased autofluorescence) assessed by FAF (Fundus autofluorescence) photography, Change in QDAF (Questionably decreased autofluorescence) assessed by FAF (Fundus autofluorescence) photography, Change in DAF (Decreased autofluorescence) assessed by FAF (Fundus autofluorescence) photography

Interventions

DRUGLBS-008

Eligibility

Sex/Gender

All

Age

0 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Change in DDAF (Definitely decreased autofluorescence) assessed by FAF (Fundus autofluorescence) photography, Change in QDAF (Questionably decreased autofluorescence) assessed by FAF (Fundus autofluorescence) photography, Change in DAF (Decreased autofluorescence) assessed by FAF (Fundus autofluorescence) photography	—

Outcome results

None listed

Source: EU CTIS · Data processed: Apr 9, 2026